Targeting Fas/FasL signaling, a new strategy for maintaining bone health

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 10, 2011, Pages 1143-1145

  Imai, Yuuki ^a   Kouzmenko, Alexander ^b   Kato, Shigeaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

bone disorder; Fas; osteoarthrosis; osteoporosis; rheumatoid arthritis

Indexed keywords

DENOSUMAB; FAS ANTIGEN; FAS LIGAND; FOLLITROPIN; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BONE DEVELOPMENT; BONE GROWTH; EPIGENETICS; HUMAN; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; BONE AND BONES; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 80052896006     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.600690     Document Type: Review

References (21)

1. Bolland MJ, Grey AB, Gamble GD, et al. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-81
2. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14
3. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603
4. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 2006;4:341-8 (Pubitemid 44645074)
5. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-25 (Pubitemid 43121814)
6. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;98:13960-5 (Pubitemid 33116006)
7. Weitzmann MN, Pacifici R. Estrogen regulation of immune cell bone interactions. Ann NY Acad Sci 2006;1068:256-74 (Pubitemid 43824158)
8. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006;125(2):247-60
9. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007;130:811-23 (Pubitemid 47332572)
10. Krum SA, Miranda-Carboni GA, Lupien M, et al. Unique ERalpha cistromes control cell type-specific gene regulation. Mol Endocrinol 2008;22:2393-406
11. Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. Embo J 2008;27:535-45 (Pubitemid 351225684)
12. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
13. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010;363:2027-35
14. Kovacic N, Grcevic D, Katavic V, et al. Targeting Fas in osteoresorptive disorders. Expert Opin Ther Targets 2010;14:1121-34
15. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
16. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-82
17. O'Brien DI, Nally K, Kelly RG, et al. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets 2005;9:1031-44 (Pubitemid 41488838)
18. Fujiki R, Chikanishi T, Hashiba W, et al. GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature 2009;459:455-9
19. Takada I, Mihara M, Suzawa M, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007;9:1273-85 (Pubitemid 350042359)
20. Kitagawa H, Fujiki R, Yoshimura K, et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 2003;113:905-17 (Pubitemid 36792033)
21. Kim MS, Kondo T, Takada I, et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009;461:1007-12